SAM
CPRX icon

Silphium Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Silphium Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-56,497
Closed -$214K – 57
2018
Q3 		$214K Hold
56,497
– – 0.06% 113
2018
Q2 		$176K Buy
+56,497
New +$171K 0.06% 97

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Silphium Asset Management's CPRX Position: Q4 2018 in Review

Silphium Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 56,497 shares — an estimated $214K sold.

Silphium Asset Management first reported a position in CPRX in Q2 2018 and held it in 2 quarters. The position peaked at $214K in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

  • Silphium Asset Management reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Silphium Asset Management sold 56,497 Catalyst Pharmaceutical shares in Q4 2018, an estimated $214K.
  • Silphium Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2018 and held it in 2 quarters.
  • Silphium Asset Management's Catalyst Pharmaceutical position peaked at $214K in Q3 2018.
  • 86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.